This statistic displays a projection of the top future inflammatory bowel disease drugs based on expected 2022 revenues worldwide . During this time , Janssen 's Stelara , a therapy targeting Crohn 's disease with expected approval in 2015 , is expected to generate 399.5 million U.S. dollars in 2022 revenues . Approximately , 1 to 1.3 million people currently suffer from IBD in the United States , however , the cause of IBD is currently unknown . IBD occurs in the colon and intestine and can also impact other parts of the body .
